Trial · NCT01688037
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Period (Week 0 to 6) | STARTED | Double-Blind Placebo, Then Open-Label 50mg | 54 | |
| Double-Blind Period (Week 0 to 6) | STARTED | Double-Blind 50mg, Then Open-Label 50mg | 28 | |
| Double-Blind Period (Week 0 to 6) | STARTED | Double-Blind 100mg/50mg, Then Open-Label 50mg | 27 | |
| Double-Blind Period (Week 0 to 6) | COMPLETED | Double-Blind Placebo, Then Open-Label 50mg | 47 | |
| Double-Blind Period (Week 0 to 6) | COMPLETED | Double-Blind 50mg, Then Open-Label 50mg | 25 | |
| Double-Blind Period (Week 0 to 6) | COMPLETED | Double-Blind 100mg/50mg, Then Open-Label 50mg | 21 | |
| Double-Blind Period (Week 0 to 6) | NOT COMPLETED | Double-Blind Placebo, Then Open-Label 50mg | 7 | |
| Double-Blind Period (Week 0 to 6) | NOT COMPLETED | Double-Blind 50mg, Then Open-Label 50mg | 3 | |
| Double-Blind Period (Week 0 to 6) | NOT COMPLETED | Double-Blind 100mg/50mg, Then Open-Label 50mg | 6 | |
| Open-Label Period (Week 6 to 12) | STARTED | Double-Blind Placebo, Then Open-Label 50mg | 47 | |
| Open-Label Period (Week 6 to 12) | STARTED | Double-Blind 50mg, Then Open-Label 50mg | 25 | |
| Open-Label Period (Week 6 to 12) | STARTED | Double-Blind 100mg/50mg, Then Open-Label 50mg | 21 | |
| Open-Label Period (Week 6 to 12) | COMPLETED | Double-Blind Placebo, Then Open-Label 50mg | 42 | |
| Open-Label Period (Week 6 to 12) | COMPLETED | Double-Blind 50mg, Then Open-Label 50mg | 22 | |
| Open-Label Period (Week 6 to 12) | COMPLETED | Double-Blind 100mg/50mg, Then Open-Label 50mg | 17 | |
| Open-Label Period (Week 6 to 12) | NOT COMPLETED | Double-Blind Placebo, Then Open-Label 50mg | 5 | |
| Open-Label Period (Week 6 to 12) | NOT COMPLETED | Double-Blind 50mg, Then Open-Label 50mg | 3 | |
| Open-Label Period (Week 6 to 12) | NOT COMPLETED | Double-Blind 100mg/50mg, Then Open-Label 50mg | 4 | |
| Follow-up Period (Week 12 to 16) | STARTED | Double-Blind Placebo, Then Open-Label 50mg | 42 | |
| Follow-up Period (Week 12 to 16) | STARTED | Double-Blind 50mg, Then Open-Label 50mg | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01688037/flow